Heparin-Binding Protein Biomarker for Early COVID-19 Relapse Warning
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective biomarkers for predicting the relapse of COVID-19 in patients during the remission period, particularly for severe cases, as existing indicators are either unreliable or delayed in detection, leading to potential deterioration and multi-organ failure.
Innovation Solution
The use of heparin-binding protein (HBP) levels as an early warning indicator, which correlates with clinical indicators and rises significantly before other markers, allowing for early intervention and prediction of relapse and inflammation progression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If traditional clinical indicators (nucleic acid tests, inflammatory markers) are used for monitoring COVID-19 patients, then viral detection and general inflammation monitoring are achieved, but early prediction of relapse in remission period is delayed or missed
Solution Approach 1:
The patent applies preliminary action by measuring HBP levels before actual relapse occurs. The HBP level changes serve as an early warning signal that precedes clinical deterioration by several days, allowing clinicians to intervene before the patient's condition actually worsens. This is demonstrated by the finding that HBP levels rise during the remission period before viral relapse, providing a window for early intervention.
Solution Approach 2:
The patent uses HBP as an intermediary biomarker that bridges the gap between viral presence and clinical symptoms. HBP levels serve as a mediator that reflects underlying pathological changes before they manifest as overt clinical relapse, allowing detection of subclinical disease progression that traditional markers miss.
2Measurement precision
If nucleic acid testing is used to monitor COVID-19 patients, then viral presence is detected, but false negatives and delayed detection of relapse occur during remission period
Solution Approach 1:
HBP serves as an intermediary marker that detects pathological changes independent of viral RNA presence. During remission, when viral RNA may be undetectable but inflammatory processes are still active, HBP levels provide reliable information about underlying disease activity, complementing nucleic acid testing.
Solution Approach 2:
The patent shifts from detecting viral presence (nucleic acid) to detecting host response (HBP levels). This parameter change allows detection of relapse through host inflammatory markers that remain elevated during viral remission, providing a different detection dimension that overcomes false negatives.
3Adaptability or versatility
If multiple clinical indicators are monitored for COVID-19 patients, then comprehensive disease assessment is achieved, but timely early warning of relapse is missed due to synchronized changes
Solution Approach 1:
HBP level measurement performs preliminary detection of relapse risk before other clinical indicators show changes. The patent demonstrates that HBP levels begin to rise during remission before inflammatory markers, coagulation parameters, and organ function indicators change, providing an advance warning signal.
Solution Approach 2:
The patent segments the disease monitoring process into distinct phases by identifying HBP as a specific marker for early relapse detection, separate from general inflammatory markers and viral detection. This segmentation allows targeted monitoring of the specific transition from remission to relapse.
Data Source
AI summary
Provided are a method for predicting a risk of deterioration of a pathogenic condition of a patient suffering a coronavirus disease (COVID-19), especially a severe patient suffering a COVID-19 and a kit thereof. The method of the present application may effectively predict the deterioration of the pathogenic condition of the patient suffering a COVID-19, thereby carrying out clinical intervention in advance, to improve prognosis of the patient suffering a COVID-19. The present application finds for the first time that the level of a heparin-binding protein (HBP) can be used as a significant indicator for early predicting relapse of the patient suffering a COVID-19, expression time of an HBP indicator is around 5 days earlier than that of a series of other clinical indicators, and thus the HBP indicator particularly has a clinical value.